

Advancements in Imaging Biomarkers for Normal Pressure Hydrocephalus

Clare Hastings*

Department of Clinical Research, University of Miami School of Medicine, Miami, Florida, USA

Abstract

Normal Pressure Hydrocephalus (NPH) is a condition characterized by an excessive accumulation of Cerebro Spinal Fluid (CSF) in the ventricles of the brain, leading to a triad of symptoms including gait disturbance, urinary incontinence and cognitive decline. NPH affects primarily elderly individuals and it is often misdiagnosed or underdiagnosed due to the overlap of symptoms with other age-related conditions such as Parkinson's disease, Alzheimer's disease, or vascular dementia. Imaging plays a critical role in the diagnosis and management of NPH and a variety of imaging markers have been proposed to aid in the differential diagnosis and prognosis of the disease. In this article, we will review the most commonly used imaging markers for NPH, including Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and cerebrospinal fluid biomarkers.

Keywords: Hydrocephalus • Computed tomography • Biomarkers

Introduction

CT scan is one of the most widely used imaging modalities for the diagnosis of NPH and it is often the first imaging test performed in patients presenting with gait disturbance, urinary incontinence and cognitive decline. CT can identify ventricular enlargement, which is a hallmark of NPH and it can also detect the presence of other conditions such as cerebral atrophy or subdural hematomas that may mimic the symptoms of NPH. However, CT is limited in its ability to detect subtle changes in the brain tissue and it has poor sensitivity and specificity for the diagnosis of NPH. MRI is the imaging modality of choice for the diagnosis of NPH and it has several advantages over CT. MRI can provide detailed images of the brain tissue, allowing for the detection of subtle changes that may not be visible on CT [1]. Moreover, MRI can quantify the volume of CSF in the ventricles and subarachnoid spaces, providing objective measurements of the severity of NPH. Several MRI markers have been proposed for the diagnosis of NPH, including ventricular size, periventricular white matter changes and aqueductal stenosis. Ventricular size is the most commonly used MRI marker for NPH and it is defined as a Ventricular Index (VI) greater than 0.3. VI is calculated by measuring the maximum width of the frontal horns of the lateral ventricles on a coronal T2-weighted image and dividing it by the maximum width of the skull [2].

Literature Review

CSF biomarkers have also been proposed as potential imaging markers for NPH. CSF biomarkers such as amyloid beta ($A\beta$), tau and phospho-tau are commonly used for the diagnosis of Alzheimer's disease and they have been shown to be altered in patients with NPH. Studies have reported that NPH patients have lower levels of $A\beta$ in the CSF compared to healthy controls, suggesting that NPH may be associated with a reduced clearance of $A\beta$ from the brain. However, the utility of CSF biomarkers in the diagnosis of NPH is still

limited and more research is needed to validate their diagnostic and prognostic value. Pressure hydrocephalus occurs when there is an obstruction or blockage in the flow of CSF, leading to a buildup of pressure within the ventricles of the brain. This increase in pressure can lead to a range of symptoms, including headaches, nausea, vomiting, dizziness and visual disturbances. In more severe cases, pressure hydrocephalus can lead to cognitive decline, seizures and even coma [3].

Discussion

There are several different types of pressure hydrocephalus, including communicating hydrocephalus, non-communicating hydrocephalus and hydrocephalus. Communicating hydrocephalus occurs when there is an obstruction or blockage in the flow of CSF within the ventricular system. Non-communicating hydrocephalus occurs when there is an obstruction or blockage in the flow of CSF outside of the ventricular system, such as in the subarachnoid space or the arachnoid granulations. Hydrocephalus ex vacuo occurs when there is a loss of brain tissue, leading to an enlargement of the ventricles and a compensatory increase in CSF pressure. The diagnosis of pressure hydrocephalus typically involves a combination of imaging studies, including Magnetic Resonance Imaging (MRI), Computed Tomography (CT) and ultrasound. MRI is often the preferred imaging modality, as it can provide detailed images of the brain and can detect subtle changes in brain tissue. CT can also be used to visualize the ventricles and detect any blockages or obstructions in the flow of CSF. Ultrasound is a non-invasive imaging technique that can be used to measure the diameter of the ventricles and assess the flow of CSF [4].

Treatment for pressure hydrocephalus typically involves the insertion of a shunt, which is a surgical device that allows for the drainage of excess CSF from the brain. Shunts are typically placed in the ventricles of the brain and are connected to a tube that runs under the skin and into the abdomen, where the excess CSF is absorbed into the bloodstream. Shunt surgery is generally effective in reducing the symptoms of pressure hydrocephalus, although there are risks associated with the procedure, including infection, blockage and malfunction. Pressure hydrocephalus is a type of hydrocephalus characterized by an increase in CSF pressure, which can lead to a range of symptoms and potential damage to brain tissue. Diagnosis typically involves a combination of imaging studies and treatment usually involves the insertion of a shunt to drain excess CSF from the brain. It is important to seek medical attention promptly if you experience any symptoms of hydrocephalus, as early diagnosis and treatment can help to prevent potential complications [5,6].

Conclusion

In conclusion, imaging markers play a crucial role in the diagnosis and

*Address for Correspondence: Clare Hastings, Department of Clinical Research, University of Miami School of Medicine, Miami, Florida, USA, E-mail: chastings30@ni.gov

Copyright: © 2023 Hastings C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 01 June, 2023; Manuscript No. jcrdc-23-107961; Editor Assigned: 03 June, 2023; Pre QC No. P-107961; Reviewed: 17 June, 2023; QC No. Q-107961; Revised: 22 June, 2023, Manuscript No. R-107961; Published: 29 June, 2023, DOI: 10.37421/2472-1247.2023.9.246

management of NPH. CT and MRI are the most commonly used imaging modalities for the diagnosis of NPH and they can provide objective measurements of the severity of the disease. Moreover, CSF biomarkers may have potential as imaging markers for NPH, although further research is needed to validate their diagnostic and prognostic value. Hydrocephalus is a medical condition characterized by the accumulation of cerebrospinal fluid in the ventricles of the brain, leading to an increase in intracranial and potentially causing damage to brain tissue. Normal pressure hydrocephalus is a type of hydrocephalus characterized by an accumulation of CSF and an increase in ICP, but with no significant increase in CSF pressure. This article will focus on pressure hydrocephalus, which is a type of hydrocephalus that is characterized by an increase in CSF pressure.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Hamre, Dorothy and John J. Procknow. "A new virus isolated from the human respiratory tract." *Proc Soc Exp Biol Med* 121 (1966): 190-193.
2. McIntosh, Kenneth, Jane H. Dees, Walter B. Becker and Albert Z. Kapikian, et al. "Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease." *Proc Natl Acad Sci* 57 (1967): 933-940.
3. Su, Shuo, Gary Wong, Weifeng Shi and Jun Liu, et al. "Epidemiology, genetic recombination and pathogenesis of coronaviruses." *Trends Microbiol* 24 (2016): 490-502.
4. Aldrich, Michael S. and Ann E. Rogers. "Exacerbation of human cataplexy by prazosin." *Sleep* 12 (1989): 254-256.
5. Aran, Adi, Ling Lin, Sona Nevsimalova and Giuseppe Plazzi, et al. "Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset." *Trends Microbiol* 32 (2009): 979-983.
6. Madeira, Catarina, Francisco Santos, Christine Kubiak and Jacques Demotes, et al. "Transparency and accuracy in funding investigator-initiated clinical trials: A systematic search in clinical trials databases." *BMJ open* 9 (2019): e023394.

How to cite this article: Hastings, Clare. "Advancements in Imaging Biomarkers for Normal Pressure Hydrocephalus." *J Clin Respir Dis Care* 9 (2023): 246.